FDA Fast Tracks Approval of Voxelotor to Treat Underlying Cause of Sickle Cell Disease | CheckRare.com
The U.S. Food and Drug Administration (FDA) has approved Oxbryta (voxelotor) to treat persons, 12 years and older, with sickle cell disease.
The U.S. Food and Drug Administration (FDA) has approved Oxbryta (voxelotor) to treat persons, 12 years and older, with sickle cell disease.
Monica Gadelha, DR, PhD, at the University of Rio De Janeiro discusses the PATHFNDR-1 trial and acromegaly.
Dr. La Piana gives advice to patients and caregivers on diagnosing adult onset leukoencephalopathy with axonal spheroids and pigmented glia.
Approval allows Onivyde (plus oxaliplatin, fluorouracil, and leucovorin) as first-line therapy.
Tyler Sandahl, MD, Clinical Pharmacist at the Mayo Clinic, discusses the use of Tocilizumab in multiple myeloma patients.
Cat Lutz, Ph.D., M.B.A. discusses how Jackson Laboratory uses mice in testing for human disease.Cat Lutz, Ph.D., M.B.A. Vice President of the Rare Disease Translational…
Monica Gadelha, DR, PhD, University of Rio De Janeiro, discusses her acromegaly research.
Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs. Below is the list of important regulatory…
Robin Kate Kelley, MD, Professor of Clinical Medicine in the Division of Hematology/Oncology, University of California, San Francisco discusses treatment options for biliary tract cancers and…
Christine Eng, Chief Medical Officer at Baylor Genetics, discusses the information her company presented at various conferences.
We have noticed an unusual activity from your IP 199.16.157.183 and blocked access to this